Condition: Acute Lymphoblastic Leukemia · Sponsor: PETHEMA Foundation
After consolidation therapy adult patients (≥18 yr) with Ph-negative ALL will be treated with continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) according to both measurable residual disease (MRD) and results of genetic study performed at baseline.
This description comes directly from the study's public registry record.
Josep Maria Ribera, Ph · 934978987 · jribera@iconcologia.net
Always discuss trial participation with your own doctor first.
| Ico-Hugtip | Badalona, Barcelona, Spain | Recruiting |
| H. A Coruña | A Coruña, Spain | Not Yet Recruiting |
| H Albacete | Albacete, Spain | Not Yet Recruiting |
| H. General Univ. de Alicante | Alicante, Spain | Recruiting |
| H. General Univ. de Alicante | Alicante, Spain | Not Yet Recruiting |
| Hospital Nuestra Señora de Sonsoles | Ávila, Spain | Recruiting |
| Clínica Teknon | Barcelona, Spain | Not Yet Recruiting |
| H del Mar | Barcelona, Spain | Not Yet Recruiting |
| H. Clínic de Barcelona | Barcelona, Spain | Recruiting |
| H. del Mar | Barcelona, Spain | Not Yet Recruiting |
| H. Sant Pau | Barcelona, Spain | Recruiting |
| H. Vall d'Hebron | Barcelona, Spain | Recruiting |
+ 96 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04179929